Novel alleles of the Transforming Growth Factor β-1 promoter and exon 1 by Arrieta Bolanos, ER et al.
 
 
Alleleb 
Positiona 
-
2410 
-
2391 
-
1985 
-
1638 
-
1347 
-
1287 
-
1169c 
-
1154 
-827 -778 -768 -469 -387 -229 -14 +29 +74 +91 
p001 A - C G T G TT C G G - C C C G C G T 
p002 - - - A - - - - - - - - - - - - - - 
p003 G AGG - - C - - - - - - - - - - T - - 
p004 G AGG G - C - - - - - - - - - - T - - 
p005 - AGG - - C A - T C - - - T - A - - - 
p006 G AGG - A C - - - - - - - - - - T - - 
p007 G - - - - - - - - - - - - - - - - - 
p008 G AGG - - C - - - - - - A - - - T - - 
p009 - - - - - - - - - A - - - - - - - - 
p010 - - - - C - - - - - - - - - - - - - 
p011 - - - - C - - - - - - - - - - T - - 
p012 - - - - - - del - - - - - - - - - - - 
p013 G AGG - - C - del - - - - - - - - T - - 
p014 - AGG - - C - - - - - C - - - - - C - 
p015 G AGG - - - - - - - - - - - G - T - - 
p016 G AGG - - - - - - - - - - - - - T - - 
p017 G - - - C - - - - - - - - - - T - G 
a.  Nucleotide position relative to the major translation start site (+1) as described in Shah R, et al. Human Genet (2006) 119: 61-74 and Shah R, 
et al. Tissue Antigens (2009) 74: 50-6.  Only positions that are polymorphic are included. 
b.  Promoter allele defined by the sequence of the regulatory region and exon 1.  Sequences are compared to allele p001 (GenBank accession no. 
AY871232). 
c.  Indicates deletion of nucleotide(s) (del). 
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Introduction 
 
Transforming growth factor β-1, encoded by the TGFB1 gene, is a cytokine that plays 
a central role in many physiologic and pathogenic processes, having pleiotropic 
effects on cell proliferation, differentiation, migration and survival. Regulatory activity 
for this gene has been demonstrated for approximately 3.0 kb between positions 
-2,665 and +423 from its translational start site. This region includes two promoter 
sites, two negative regulatory elements and two enhancers, in addition to part of the 
protein’s signal peptide. An important amount of polymorphism has been reported for 
this gene, including 17 promoter and exon 1 alleles defined on the basis or 18 
polymorphisms (Table 1). Polymorphism in TGFB1 has been associated to 
differential levels of expression of this cytokine and to genetic risk in cancer and 
hematopoietic stem cell (HSCT) and organ transplantation. In this report, we extend 
this list by presenting novel alleles formed by new polymorphic positions and a new 
combination of the previously described polymorphisms. These novel alleles have 
been found during the typing of a cohort of unrelated haematopoietic stem cell 
transplantation patient-donor pairs, and of healthy volunteer donors.  
 
 
 
 
Conclusions and future work 
 
Our results show a considerable extent of unreported variation within TGFB1’s 
promoter and exon 1. Most of the new SNP found lie in either known regulatory 
regions such as enhancers, promoters or negative regulatory elements, or in the 
coding translated region of exon 1 causing amino acid changes in at least one case. 
All these variation is bound to have an effect in the regulation of this important gene. 
Knowledge of the extent and consequences of this variation are fundamental for 
understanding the immunogenetics of Transforming growth factor β-1 and its possible 
applications in Medicine.  
 
We are currently continuing our analysis of the effect of polymorphisms within the 
regulatory region of TGFB1 on the outcome of unrelated donor HSCT and on the 
function of regulatory T cells. These data will hopefully help to identify the risk factors 
associated with TGFB1 expression in patients and donors and to generate clinically 
useful algorithms of genetic risk assessment in HSCT.   
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Results 
 
During the typing of 627 samples from the patient-donor cohort, a total of 12 new 
polymorphisms have been identified. Approximately 3% of the samples showed the 
presence of these new single nucleotide polymorphisms (SNP). Six of these SNP 
have been isolated and shown to be carried in alleles otherwise identical to the 4 
frequent TGFB1 promoter and exon 1 alleles found to occur in the patient-donor 
cohort (i.e. p001, p003, p006, p014). SNP at -498, -1569 and -2069 have been found 
in the context of p003, while those at -1743, -1878 and -1922 are carried by a p001-
like allele. We are continuing the phase definition for the remainder of the new SNP. 
 
The family study of the unsolvable genotype in a healthy donor revealed that the 
novel allele was carried by the subject’s father, while the mother was homozygous for 
p001. The subject and the sibling had the same genotype. As shown in Table 2 and 
confirmed by sequencing in isolation, the new allele is formed by a new combination 
of variants at positions -2410(A), -2391(AGG+), -1347(C) and +29(C), without 
polymorphism at positions -768(-) and +74(G).      
  
Figure 1 TGFB1 regulatory region. The gene’s promoter 
and exon 1 region analysed in this study is shown 
schematically and not to scale. Previously known variants 
that define known alleles are shown in blue, while novel 
variant positions discovered in this study are shown in red.	

Materials and Methods 
 
DNA from the Anthony Nolan Research Institute’s sample repository has been used for 
the typing of a 3.0 kb region encompassing TGFB1’s promoter and exon 1. Peripheral 
blood from healthy volunteer donors was obtained by venipuncture. DNA was 
extracted by an in-house salting-out method. Molecular typing was carried out by an 
in-house amplification of 4 regions (~750 kb each) in TGFB1’s promoter and exon 1, 
followed by sequencing with M13 primers. Samples found to have previously 
unreported polymorphisms were confirmed by either (1) whole-region amplification 
followed by molecular cloning (Zero Blunt TOPO PCR Cloning Kit, Invitrogen) and/or 
(2) phase-specific whole-region amplification using primers specific for the -2391AGG 
duplication, both followed by sequencing in isolation.  
In the case of the healthy volunteer donor, a previously unreported combination of the 
basic 18 polymorphic positions was suspected because the sample’s genotype could 
not be inferred. A family study was designed and samples of the subject’s parents and 
of one sibling were analysed. 	

-2410 -2391 -1638 -1347 -768 +29 +74 
Subject AA AGG/- GG C/T -/- CC GG p001/? 
Mother AA -/- GG TT -/- CC GG p001/p001 
Father G/A AGG/AGG GG CC -/- T/C GG p003/? 
Table 1 Known TGFB1 regulatory region alleles. Alleles as defined by Shah R, et 
al. 2006 and 2009 are formed by combinations of genotypes found in 18 polymorphic 
positions within TGFB1’s exon 1 and upstream regulatory region. 	
 Table 2 Results of family study of a new allele of TGFB1’s regulatory region.	

5’ UTR S
P -2665 
-2410A>
G 
-1740C>T -1347C>T -1287G>
A 
-1169_-1170delTT 
-1154C>T 
-827G>C 
-778G>A 
-768_-769insC -469C>
A +29T>C 
+74G>C 
+423 
-2204 -2201 -1971 -1570 -1292 -1161 -839 -568 +1 +354 
E2 E1 N2 N1 P1 P2 
Exon 1 
+91T>G -229C>
G 
-498C>
G 
-1638G>
A 
-1569C>T 
-1826C>
A 
-1922C>
A -144G>
A 
+149G>
C 
-14G>A 
-73G>A -265C>
G 
-387C>
T 
-2069G>
A 
-2001C>
G 
-1985C>
G 
+342C>
T 
-2389_-2391dupAGG 
-2219G>
C 
-2316C>
